{"DataElement":{"publicId":"6035078","version":"1","preferredName":"Prostate Cancer Prior Outcome of Therapy Text","preferredDefinition":"Text description of the prior outcome of therapy for prostate cancer.","longName":"PRIOR_OUTC_THRP_TXT","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"6034918","version":"1","preferredName":"Prostate Carcinoma Prior Outcome of Therapy","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002_Earlier in time or order._The result of therapy for a given disease or condition in a patient or group of patients.","longName":"2744055v1.0:6034916v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"2744055","version":"1","preferredName":"Prostate Carcinoma","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002","longName":"C4863","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B8AEEC8-FDF2-03F8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-04-23","modifiedBy":"ONEDATA","dateModified":"2008-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6034916","version":"1","preferredName":"Prior Outcome of Therapy","preferredDefinition":"Earlier in time or order.:The result of therapy for a given disease or condition in a patient or group of patients.","longName":"C25629:C18919","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome of Therapy","conceptCode":"C18919","definition":"The result of therapy for a given disease or condition in a patient or group of patients.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F23D72A-1947-60FA-E053-F662850AE651","latestVersionIndicator":"Yes","beginDate":"2017-11-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-11-29","modifiedBy":"ONEDATA","dateModified":"2017-11-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008563","version":"1","preferredName":"Therapy Results","preferredDefinition":"the results or effects (does not include CTC Adverse Events) of therapeutic agents or procedures administered to the patient.","longName":"TX_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6690D31-4081-494A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-06","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F23D72A-1958-60FA-E053-F662850AE651","latestVersionIndicator":"Yes","beginDate":"2017-11-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-11-29","modifiedBy":"COOPERM","dateModified":"2017-12-04","changeDescription":"Created for Dr. Turkbey P173316 request 11.21.17 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2666622","version":"2","preferredName":"100 Character Text","preferredDefinition":"Text; the words of something written.","longName":"2666622v2.0","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008581","version":"1","preferredName":"Properties or Attributes","preferredDefinition":"NCI Thesarurus C20189","longName":"PropertiesOrAttributes","context":"caCORE","contextVersion":"1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C4F36F0A-BEBB-047F-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-08-15","endDate":null,"createdBy":"DWARZEL","dateCreated":"2003-08-15","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234203","version":"1","preferredName":"Text","preferredDefinition":"Text; the words of something written.","longName":"C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F89B-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"2D410E9E-49F0-D096-E050-BB89AD432B9D","latestVersionIndicator":"Yes","beginDate":"2007-07-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-03-04","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/30/17 tt transferred context, added reg status and CSI per Round 5 finalization task.  3/4/16 jk versioned to remove qualifers.  7/20/07 jc created to support ACRIN Breast CDEs","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Prior treatment effects","type":"Preferred Question Text","description":"Prior treatment effects","url":null,"context":"CCR"}],"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F3974CC-E386-687A-E053-F662850A7039","latestVersionIndicator":"Yes","beginDate":"2017-11-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-11-30","modifiedBy":"COOPERM","dateModified":"2017-12-04","changeDescription":"Created for Dr. Turkbey P173316 request 11.21.17 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}